Abstract
Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the Km values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. However, the scope of the “albumin effect” is unknown. In this investigation we characterized the effects of albumin on the kinetics of 4-methylumbelliferone (4MU) glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, 1A6, and 1A9, and propofol (PRO) glucuronidation by UGT1A9 and HLM. BSA and HSAFAF, but not human serum albumin, reduced the Km values for 4MU and PRO glucuronidation by UGT1A9. For example, HSAFAF (2%) reduced the Km values for 4MU and PRO glucuronidation from 13.4 to 2.9 and 41 to 7.2 μM, respectively. Similarly, HSAFAF (2%) reduced the Km for PRO glucuronidation by HLM from 127 to 10.6 μM. Arachidonic, linoleic, and oleic acids and a mixture of these decreased the rates of 4MU and PRO glucuronidation by UGT1A9. Km values for these reactions were increased 3- to 6-fold by the fatty acid mixture. Inhibition was reversed by the addition of BSA (2%). Extrapolation of kinetic constants for PRO glucuronidation by HLM in the presence of HSAFAF predicted in vivo hepatic clearance within 15%. Fatty acids had no effect on 4MU glucuronidation by UGT1A1 and UGT1A6 but, paradoxically, all forms of albumin altered the kinetic model for 4MU glucuronidation by UGT1A6 (from Michaelis-Menten to two-site). Only BSA caused a similar effect on 4MU glucuronidation by UGT1A1. It is concluded that BSA and HSAFAF reduce the Km values of only those enzymes inhibited by long-chain unsaturated fatty acids.
Footnotes
-
This work was funded by a grant from the National Health and Medical Research Council of Australia. A.R. is the recipient of a Flinders University Postgraduate Research Scholarship.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.108.021105.
-
ABBREVIATIONS: UGT, UDP-glucuronosyltransferase; IV-IVE, in vitro-in vivo extrapolation; HLM, human liver microsomes; BSA, bovine serum albumin; HSAFAF, human serum albumin, fatty acid-free; HSA, human serum albumin; 4MU, 4-methylumbelliferone; PRO, propofol; 4MUG, 4-methylumbelliferone β-D-glucuronide; UDPGA, UDP-glucuronic acid; HPLC, high-performance liquid chromatography; PRO-Gluc, propofol glucuronide; FAM, fatty acid mixture (40% C18:1, 40% C18:2, and 20% C20:4).
- Received February 17, 2008.
- Accepted March 20, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|